Receiving more TMS sessions in a single day does not mean the treatment is more dangerous. Multiple well-designed studies — including a pivotal trial published in The American Journal of Psychiatry (Cole et al., 2020) — have shown that accelerated protocols, are generally safe, well-tolerated, and effective. The safety profile remains comparable to traditional, once-daily approaches.

Accelerated TMS isn’t reserved only for patients with more “intense” or treatment-resistant symptoms. In fact, one-day treatment protocols often yield higher response rates compared to traditional 36-session courses, meaning all patients, not just those with more severe symptoms, could benefit from the opportunity of a higher likelihood of remission in a shorter period.

The choice of protocol is often more about logistics, access, and patient preference — not symptom intensity. All patients who qualify for TMS under standard clinical guidelines could potentially benefit from accelerated delivery, as it’s a safe and effective option for a broad range of individuals.

The idea of “accelerated” or “faster” TMS is not experimental or fringe — it has been part of the field’s development for years. Leading academic centers and clinical practices have successfully implemented these protocols with positive outcomes. While newer to some community settings, it is well-supported in the literature and increasingly embraced across the industry.

It’s important to clarify that while our accelerated TMS protocol shares some surface-level similarities with the Stanford SAINT protocol, they are not the same — and that’s by design.

SAINT (Stanford Accelerated Intelligent Neuromodulation Therapy) is a highly specialized research protocol with unique features such as fMRI-guided targeting, ultra-high pulse dosing, and tightly controlled session timing over the course of five days. It’s an impressive advancement in a research setting — but not yet scalable or accessible for most clinical environments.

With SAINT’s success in achieving remission in just five days, researchers began exploring whether even shorter timelines were possible. But they quickly encountered a natural barrier: the brain tends to plateau. Beyond a certain number of sessions in a day, more stimulation wasn’t harmful — but it also didn’t lead to significantly better outcomes.

That’s where our protocol breaks new ground. By introducing neuroplasticity-enhancing medications, we help the brain remain receptive throughout the day — effectively overcoming the plateau and allowing for a more condensed, effective course of TMS. This integration allows us to safely reduce total treatment time while maintaining or even improving the brain’s response demonstrating higher response and remission rates.

While foundational accelerated pushed the science forward, we’re bringing that progress to patients in One-Day.

One-Day TMS™ is a cash-pay treatment and is not covered by insurance. The full cost of treatment is $5,500. We are committed to making care accessible — reduced rates may be available for individuals with Medicare or Medicaid, military personnel, and households who qualify based on income levels.

Additionally, we believe travel should never be a barrier to healing. Patients traveling significant distances may be eligible for travel assistance. Please contact us to learn more about available financial support.